Details for Patent: 7,407,955

Which drugs does patent 7,407,955 protect, and when does it expire?

Patent 7,407,955 protects JENTADUETO XR, TRIJARDY XR, GLYXAMBI, JENTADUETO, and TRADJENTA, and is included in five NDAs.

Protection for JENTADUETO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and six patent family members in thirty-eight countries.

Summary for Patent: 7,407,955

Title:	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Abstract:	The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Warthausen, DE), Eckhardt; Matthias (Biberach, DE), Mark; Michael (Biberach, DE), Maier; Roland (Biberach, DE), Lotz; Ralf R. H. (Schemmerhofen, DE), Tadayyon; Mohammad (Ulm, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)
Application Number:	10/639,036
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,407,955
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,407,955

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No					Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes					Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 7,407,955

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 38 243	Aug 21, 2002
Germany	103 12 353	Mar 20, 2003

International Family Members for US Patent 7,407,955

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	041025
Argentina	077875
Argentina	087287
Austria	453644
Australia	2003253418
Australia	2010201384
Australia	2013202252